FLGT

Based on Fulgent Genetics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Fulgent Genetics do?

Fulgent Genetics provides molecular diagnostic and genetic testing services to physicians, patients, and insurers. Its test menu covers oncology panels, carrier screening, whole genome sequencing, and COVID-19 detection. The company processes tests through its proprietary sequencing platform and serves customers in the United States and internationally.

Does FLGT pay dividends?

No, Fulgent Genetics does not currently pay a dividend. The company retains capital to support its operations and invest in expanding its specialty genetic testing capabilities. Investors seeking dividend income should look elsewhere in the healthcare sector.

When does FLGT report earnings?

Fulgent Genetics follows a standard quarterly earnings reporting schedule. Specific dates are not covered by our data source — check the company's investor relations page for the most current schedule and recent results.

Is FLGT a good stock to buy?

UQS Score rates FLGT as Poor, driven by Weak readings across Quality, Moat, and Growth pillars. The Risk pillar is a relative bright spot, but the Elevated Valuation rating suggests the stock may not be priced to reflect its current fundamental challenges. The full pillar breakdown is available to Pro members.

Is FLGT overvalued?

The UQS Valuation pillar for FLGT is rated Elevated, indicating the current market price appears high relative to the company's underlying financial profile. Given Weak Growth and Quality ratings, the valuation gap is a notable concern for investors evaluating entry points.

How does FLGT compare to its competitors?

Among peers like Myriad Genetics and Personalis, Fulgent differentiates through its broad test menu and proprietary sequencing technology. However, its Poor overall UQS Score suggests it currently lags on quality and moat metrics relative to more established diagnostics companies. The competitor comparison table on this page provides a side-by-side UQS view.

What is FLGT's market cap bracket?

Fulgent Genetics is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but also carries higher volatility and liquidity risk compared to large- or mega-cap healthcare names.

Who founded Fulgent Genetics?

Fulgent Genetics was founded in 2016. Founding details, including the names of its founders, are publicly available through the company's official filings and investor relations materials.

Is FLGT a long-term quality investment?

As a long-term quality indicator, the UQS Score for FLGT currently rates as Poor. Weak Moat and Quality pillar scores suggest the company has not yet established the durable competitive advantages typically associated with long-term compounders. The Risk pillar's Good rating offers some stability, but sustained improvement across other pillars would be needed to change this picture.

What is the main competitive advantage of Fulgent Genetics?

Fulgent's proprietary sequencing platform and broad, flexible test menu allow it to offer a wide range of genetic tests without relying entirely on third-party technology. However, the UQS Moat pillar rates this advantage as Weak, suggesting competitors have been able to replicate or surpass key elements of its offering.

What sector does FLGT belong to?

Fulgent Genetics operates in the Healthcare sector, specifically within molecular diagnostics and genetic testing services. It sits at the intersection of clinical laboratory services and genomics, a segment that has seen significant growth and competition over the past several years.

Fulgent Genetics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Fulgent Genetics, Inc. shows steady but unspectacular growth, typical for mature companies.

Fulgent Genetics, Inc. maintains a reasonable risk profile with manageable debt levels.

Fulgent Genetics, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Fulgent Genetics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for FLGT.

The UQS (Unified Quality Score) for Fulgent Genetics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Fulgent Genetics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Fulgent Genetics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.